Clinical Trials Search

The Influence on Time to Progression of Adriamycin + Dexrazoxane vs No Treatment in Female Patients with Advanced or Metastatic Breast Cancer After Treatment with Six Courses of CAF

Protocol:

880-50

Category:
Breast
Department:
Oncology
Status:
CLOSED TO ACCRUAL
  • Eligibility:
    Click Here to View
    1.0) Adjuvant chemo =6 mo prior is OK.
    2.0) No Anthracyclines.
    3.0) No chemo for mets allowed.
    4.0) Prior RT OK.
    5.0) No CNS mets.

    Drugs: CAF, Dexrazoxane(provided)
  • Consent forms:
    You must be logged in to view the documents.
  • Protocols:
    You must be logged in to view the documents.

A Trial of Adjuvant Chemoradiation After Gastric Resection for Adenocarcinoma, Phase III

Protocol:

90-41-51

Category:
Stomach
Department:
Oncology
Status:
CLOSED TO ACCRUAL
  • Eligibility:
    Click Here to View
    1.0) Path (+) adeno of stomach or GE junction.
    2.0) Must have had "en bloc" resection of all tumor and be at high risk for later failure.
    3.0) No ascites, peritoneal seeding, liver mets or extra-ABD mets.

    4.0) 20-40 days postop to registration
    5.0) PS 0-2.
    6.0) No prior RT, chemo or immunotherapy.

    Drugs: 5-FU, Leucovoren
    7.0)
    8.0)
  • Consent forms:
    You must be logged in to view the documents.
  • Protocols:
    You must be logged in to view the documents.

A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior To Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer

Protocol:

90203

Category:
Prostate
Department:
Oncology
Status:
CLOSED TO ACCRUAL
  • Eligibility:
    Click Here to View

    -Histologically confirmed adenocarcinoma of the prostate
    -No small cell, neuroendocrine, or transitional cell carcinoma
    -Clinically localized, stage T1-3a disease
    -No radiographic evidence of metastatic disease
    -Serum prostate-specific antigen level <= 100 ng/mL within the past 6 weeks
    -Patients must have high-risk disease determined by EITHER--
    --Probability of biochemical progression-free survival at 5 years after surgery < 60% by Kattan nomogram prediction or
    --Prostate biopsy gleason sum greater than or equal to 8
    -Patients must be deemed an appropriate candidate for radical prostatectomy
    -No prior treatment for prostate cancer, including surgery, pelvic lymph node dissection, radiotherapy, or chemotherapy
    -ECOG performance status 0-2 

  • Consent forms:
    You must be logged in to view the documents.
  • Protocols:
    You must be logged in to view the documents.

Phase II Trial: Evaluation of the Role of Multiple Metastasectomy Combined with Systemic and Hepatic Artery Infusion Chemotherapy for Colorectal Carcinoma Metastatic to the Liver

Protocol:

92-46-52

Category:
Colon and Rectal
Department:
Oncology
Status:
CLOSED TO ACCRUAL
  • Eligibility:
    Click Here to View
    1.0) Ability to withstand operative procedure.
    2.0) Patients may have received prior adjuvant 5FU with or without levamisole and/or leucovorin.
    Drugs: Floxuridine, 5-FU, Leucovorin
  • Consent forms:
    You must be logged in to view the documents.
  • Protocols:
    You must be logged in to view the documents.

A Phase I/II Dose Escalation Study using Thre Dimensional Conformal Radiation Therapy in Patients with Inoperable, Non-Small Cell Lung Cancer

Protocol:

93-11

Category:
Lung
Department:
Oncology
Status:
CLOSED TO ACCRUAL
  • Eligibility:
    Click Here to View
    1.0) Stage I-IIIB (unresected).
    2.0) PS >70
    3.0) No malignant pleural effusion, positive supraclavicular nodes, or massive atelectasis.

  • Consent forms:
    You must be logged in to view the documents.
  • Protocols:
    You must be logged in to view the documents.

A Randomized Phase II Trial of Different Schedules of Topotecan for the Treatment of Extensive-Stage Small Cell Lung Cancer

Protocol:

93-20-53

Category:
Lung
Department:
Oncology
Status:
CLOSED TO ACCRUAL
  • Eligibility:
    Click Here to View
  • Consent forms:
    You must be logged in to view the documents.
  • Protocols:
    You must be logged in to view the documents.

Phase I/II Study of Chemo-Radiotherapy Used Pre-Operatively or Definitively in Carcinoma of the Esophagus or GE Junction

Protocol:

94-474

Category:
Esophageal
Department:
Oncology
Status:
CLOSED TO ACCRUAL
  • Eligibility:
    Click Here to View
    1.0) Path (+) squamous cell or adeno CA of esopha/GE junction
    2.0) T1-2,Nx-N1,M0.
    3.0) PS 0-2.

    Drugs: Cisplatinum, 5FU
  • Consent forms:
    You must be logged in to view the documents.
  • Protocols:
    You must be logged in to view the documents.

Phase I/II Study of Post-Cryosurgery (Salvage) Radiotherapy in Carcinoma of the Prostate

Protocol:

94-476

Category:
Prostate
Department:
Oncology
Status:
CLOSED TO ACCRUAL
  • Eligibility:
    Click Here to View
    1.0) Residual tumor in prostate, periprostatic tissue following definitive cryosurg.

    2.0) PS 0-2
    3.0) No prior pelvic RT

    Drug: Not applicable
  • Consent forms:
    You must be logged in to view the documents.
  • Protocols:
    You must be logged in to view the documents.

Colorectal Adenoma Chemoprevention Trial Using Aspirin: A Phase III Study

Protocol:

94-92-51

Category:
Colon and Rectal
Department:
Oncology
Status:
CLOSED TO ACCRUAL
  • Eligibility:
    Click Here to View
    1.0) Path (+) colon or rectal cancer.
    2.0) Age >30 and <75.
    3.0) No current chemo or RT.
    4.0) No NSAID use or contraindications to aspirin use.
    5.0) No familial polyposis, active malignancy or inflammatory bowel dz
    6.0)
    7.0) No immunosuppressive therapy w/in 6 mo. preceeding study entry.

    Drug: Aspirin (provided)
  • Consent forms:
    You must be logged in to view the documents.
  • Protocols:
    You must be logged in to view the documents.

Phase III Double-Blind Placebo-Controlled Trial to Assess the Effectiveness of Sucralfate in the Prevention of Treatment-Induced Diarrhea in Patients Receiving Pelvic Radiation Therapy

Protocol:

94-92-52

Category:
Cancer Control
Department:
Oncology
Status:
CLOSED TO ACCRUAL
  • Eligibility:
    Click Here to View
  • Consent forms:
    You must be logged in to view the documents.
  • Protocols:
    You must be logged in to view the documents.